3 Dow Stocks to Own as the Dollar Supply Breaks Record High
This year the money supply has recovered almost two whole months early, which means we could be heading for an exceptionally strong fourth quarter for stocks.
All Work
Trey Thoelcke
Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
The 6 Most Shorted NYSE Stocks: GE Comes Out on Top
While short sellers shied away from many of the most heavily shorted stocks traded on the New York Stock Exchange between the June 15 and June 30 settlement dates, GE bucked that trend.
The 6 Most Shorted Nasdaq Stocks: Bye-Bye Apple
Among the most heavily shorted stocks traded on the Nasdaq, the moves between the June 15 and June settlement dates were mostly mixed and modest.
3 Stocks Unexpectedly Benefiting From Low Gas Prices
A new JPMorgan study suggests that the reduction in average gas prices in the United States has not resulted in an increase in savings.
Is Too Big to Fail Coming to a Health Care Sector Near You?
The fact that major health care mergers were announced at the same time that the Affordable Care Act began to take full effect is no coincidence.
3 Stocks to Watch as China Stabilizes
China just surprised the markets by reporting an unexpected rise in capital inflows. It could signal the stabilization of the second largest economy in the world.
3 Stocks Set to Benefit From a Tighter Jobs Market
Employment data out of the United States came out better than expected this week. Here are three of the leading recruitment stocks to look at in this tight jobs market.
If Investment Banks Know Financial Markets So Well, Why Are Their Stocks So Low?
It may come as a shock, but out of the 10 largest investment banks by assets, only one of them has outperformed the S&P 500 since bear market bottom on March 6, 2009.
As Interest Rates Again Reach Record Lows, Watch Out for the Yield Curve
After all the talk of interest rate hikes and gradually tightening monetary policy from the Federal Reserve, interest rates on the 10-year bond have touched record lows yet again.
How to Trade European Bank Stocks on the Brexit Vote
Some of the most feared stocks in the world right now are European banks, but this also makes them rife with opportunity.
Volkswagen Recovering Nicely as Memory of Dieselgate Fades
The day before news of the Volkswagen diesel emission scandal broke, the stock was trading at $38 over the counter. As of June 17, we are sitting just above $29. As of Volkswagen’s last…
A Quick Look of E3 and the Gaming Stocks Involved
Here’s a look at how some of the public companies presenting at E3 fared, and what the rest of the year looks like in light of this.
Net Neutrality Winners and Losers
Here's a look at which companies win and which ones lose on the latest net neutrality ruling, or at least which will be perceived as winners and losers.
As Ford Gazes Into the Future, It Should Keep an Eye on the Present
With an era of self-driving cars on the horizon, and faced with the rising millennial generation that shows little interest in auto ownership, Ford must be wondering about its future.
2 Stocks to Buy Post-Brexit
Here are two stocks that likely will benefit from the chaos that surely will ensue if the United Kingdom votes to leave the European Union on June 23.
The Fed Entering a Potentially Embarrassing Situation That Could Signal Bond Market Double Top
If the Federal Open Market Committee (FOMC) ends up voting to hold the target fed funds rate as is, then a potentially embarrassing situation for the Fed could develop.
Some Popular Obamacare Plans About to See Big Price Hikes?
Users of some popular Affordable Care Act plans may face sticker shock in the coming year, according to a study by the Kaiser Family Foundation released on Wednesday.
2 Very Different Stocks Set to Benefit From a Commodities Boom
Commodities look like they are about to end their half-decade slump, which may kick off a bull run that could last into the next decade.
3 Biotechs That Just Announced Successful Phase 2 Trials
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.